Drug Profile
Research programme: respiratory syncytial virus infection therapeutics - ReViral
Alternative Names: RSV fusion back-up protein inhibitors - ReViral; RSV fusion protein inhibitors - ReViral; RSV replication inhibitors - ReViralLatest Information Update: 14 Jun 2022
Price :
$50
*
At a glance
- Originator ReViral
- Class Antivirals; Small molecules
- Mechanism of Action Viral fusion protein inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections